Ruth E. March
Impact in
- Pharmacology top 0.5%
- Pharmacogenetics and Drug Metabolism
- Drug-Induced Hepatotoxicity and Protection
- Nephrology top 2%
- Renal Diseases and Glomerulopathies
Papers in
- Genetics 16
- Genomics and Rare Diseases 8
- Genetic Associations and Epidemiology 8
-
- Pharmacogenetics and Drug Metabolism 6
- Co-authors
- Menelas N. Pangalos (2 shared papers)Paul Morgan (2 shared papers)Robert Alexander (1 shared paper)Dearg S. Brown (1 shared paper)David R. Cook (1 shared paper)Yu Zong Chen (1 shared paper)Raeanne Cristine Moore (1 shared paper)Dennis W. Schneck (1 shared paper)
- Journals
- Pharmacogenomics (3 papers)Nature (3 papers)Clinical Cancer Research (2 papers)Nature Genetics (2 papers)Yeast (2 papers)
- Partner nations
- United KingdomUnited StatesSweden
In The Last Decade
Ruth E. March
41 papers receiving 3.9k citations
Ruth E. March's Hit Papers
Peers
Comparison fields: 5 of 148
- Pharmacology 504
- Nephrology 309
- Genetics 778
- Computational Theory and Mathematics 418
- Immunology 369
Countries citing papers authored by Ruth E. March
This map shows the geographic impact of Ruth E. March's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruth E. March with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruth E. March more than expected).
Fields of papers citing papers by Ruth E. March
This network shows the impact of papers produced by Ruth E. March. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruth E. March. The network helps show where Ruth E. March may publish in the future.
Co-authors
The 25 scholars most cited alongside Ruth E. March, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 41 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework Hit paper breakdown → | 2014 | 1079 |
| 2 | Diagnostic Utility of Exome Sequencing for Kidney Disease Hit paper breakdown → | 2018 | 537 |
| 3 | 2005 | 409 | |
| 4 | Rare variant contribution to human disease in 281,104 UK Biobank exomes Hit paper breakdown → | 2021 | 341 |
| 5 | Impact of a five-dimensional framework on R&D productivity at AstraZeneca Hit paper breakdown → | 2018 | 323 |
| 6 | 2007 | 317 | |
| 7 | Advancing human genetics research and drug discovery through exome sequencing of the UK Biobank Hit paper breakdown → | 2021 | 258 |
| 8 | 1998 | 122 | |
| 9 | 2023 | 102 | |
| 10 | 2004 | 80 | |
| 11 | 1998 | 70 | |
| 12 | 2006 | 54 | |
| 13 | 2019 | 40 | |
| 14 | 2001 | 40 | |
| 15 | 2000 | 37 | |
| 16 | 2021 | 35 | |
| 17 | 2022 | 29 | |
| 18 | 2025 | 28 | |
| 19 | 2002 | 26 | |
| 20 | 2024 | 25 |
About Ruth E. March
Ruth E. March is a scholar working on Genetics, Pharmacology, Immunology, Oncology and Cancer Research, having authored 41 papers that have together received 4.2k indexed citations. Recurring topics across this work include Genomics and Rare Diseases (8 papers), Genetic Associations and Epidemiology (8 papers), Pharmacogenetics and Drug Metabolism (6 papers), Cancer Genomics and Diagnostics (4 papers), Computational Drug Discovery Methods (4 papers), Statistical Methods in Clinical Trials (3 papers), Biosimilars and Bioanalytical Methods (3 papers) and Pharmaceutical Economics and Policy (3 papers). The work is most often cited by research in Pharmacology (504 citations), Nephrology (309 citations), Genetics (778 citations), Computational Theory and Mathematics (418 citations) and Immunology (369 citations). Ruth E. March has collaborated with scholars based in United Kingdom, United States and Sweden. Frequent co-authors include Menelas N. Pangalos, Paul Morgan, Robert Alexander, Dearg S. Brown, David R. Cook, Yu Zong Chen, Raeanne Cristine Moore, Dennis W. Schneck, Eminy H.Y. Lee and S RYAN. Their work appears in journals such as Pharmacogenomics, Nature, Clinical Cancer Research, Nature Genetics and Yeast.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.